These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Lenert A; Lenert P Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919 [TBL] [Abstract][Full Text] [Related]
4. The role of biologics in treatment of ANCA-associated vasculitis. Dharmapalaiah C; Watts RA Mod Rheumatol; 2012 Jun; 22(3):319-26. PubMed ID: 22038317 [TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Jones RB Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382 [TBL] [Abstract][Full Text] [Related]
6. Management of ANCA associated vasculitis. Wallace ZS; Miloslavsky EM BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597 [TBL] [Abstract][Full Text] [Related]
7. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Timlin H; Lee SM; Manno RL; Seo P; Geetha D Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088 [TBL] [Abstract][Full Text] [Related]
8. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR; Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829 [TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long? de Joode AA; Sanders JS; Rutgers A; Stegeman CA Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i150-8. PubMed ID: 25609739 [TBL] [Abstract][Full Text] [Related]
12. L44. Management of relapses in vasculitis. Mouthon L Presse Med; 2013 Apr; 42(4 Pt 2):619-22. PubMed ID: 23477710 [No Abstract] [Full Text] [Related]
13. Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring. Wang T; Weigt SS; Belperio JA; Lynch JP Semin Respir Crit Care Med; 2011 Jun; 32(3):346-70. PubMed ID: 21674420 [TBL] [Abstract][Full Text] [Related]
14. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? Kallenberg CG Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946 [TBL] [Abstract][Full Text] [Related]
15. Seven clinical conundrums in the treatment of ANCA-associated vasculitis. Alba MA; Flores-Suárez LF Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S74-83. PubMed ID: 23663685 [TBL] [Abstract][Full Text] [Related]
16. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Faurschou M; Westman K; Rasmussen N; de Groot K; Flossmann O; Höglund P; Jayne DR; Arthritis Rheum; 2012 Oct; 64(10):3472-7. PubMed ID: 22614882 [TBL] [Abstract][Full Text] [Related]
18. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? Tesar V; Hruskova Z Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512 [TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and management of small vessel vasculitides]. Pettersson T; Karjalainen A Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753 [TBL] [Abstract][Full Text] [Related]
20. Vasculitis and Pregnancy. Machen L; Clowse ME Rheum Dis Clin North Am; 2017 May; 43(2):239-247. PubMed ID: 28390566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]